PHVS (Pharvaris NV) FFO


PHVS Pharvaris NV PHVS
22 GF Score
Price $35.02
! 3 Warning Signs
View Full Analysis

What is Pharvaris NV FFO?

FFO (Funds from operations) only applies to REITs.

PHVS
22GF Score
Pharvaris NV PHVS
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharvaris NV Business Description

Other Exchanges 9EN:Germany
Address Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
22GF Score

Get the complete analysis for PHVS

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.02
Price